FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 161 filers reported holding FATE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $21,456,000 | -18.7% | 362,000 | +19.1% | 0.42% | -10.7% |
| Q2 2021 | $26,384,000 | +5.3% | 304,000 | 0.0% | 0.47% | -11.0% |
| Q1 2021 | $25,065,000 | -51.1% | 304,000 | -46.1% | 0.53% | -48.0% |
| Q4 2020 | $51,291,000 | +92.1% | 564,067 | -15.6% | 1.01% | +56.0% |
| Q3 2020 | $26,703,000 | -14.8% | 668,067 | -26.9% | 0.65% | -28.8% |
| Q2 2020 | $31,352,000 | -12.7% | 913,775 | -43.5% | 0.91% | -19.9% |
| Q1 2020 | $35,913,000 | -8.4% | 1,616,993 | -19.3% | 1.14% | -8.8% |
| Q4 2019 | $39,191,000 | +29.2% | 2,002,605 | +2.5% | 1.25% | +1.1% |
| Q3 2019 | $30,328,000 | -12.3% | 1,952,897 | +14.7% | 1.24% | -0.5% |
| Q2 2019 | $34,569,000 | +15.5% | 1,702,897 | 0.0% | 1.24% | +8.3% |
| Q1 2019 | $29,920,000 | +40.9% | 1,702,897 | +2.9% | 1.15% | +34.9% |
| Q4 2018 | $21,232,000 | +11.1% | 1,654,865 | +41.0% | 0.85% | +24.1% |
| Q3 2018 | $19,118,000 | – | 1,173,617 | – | 0.68% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $46,987,000 | 60.92% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $278,604,000 | 36.08% |
| Darwin Global Management, Ltd. | 1,370,133 | $112,967,000 | 22.12% |
| Redmile Group, LLC | 12,957,222 | $1,068,323,000 | 15.05% |
| Copernicus Capital Management, LLC | 8,000 | $660,000 | 10.66% |
| Casdin Capital, LLC | 3,400,000 | $280,330,000 | 8.35% |
| Grosvenor Holdings, L.L.C. | 1,123,576 | $92,639,000 | 6.81% |
| DAFNA Capital Management LLC | 314,360 | $25,919,000 | 6.15% |
| Ally Bridge Group (NY) LLC | 270,000 | $22,262,000 | 4.27% |
| Ghost Tree Capital, LLC | 185,000 | $15,253,000 | 3.58% |